Key result
Genomics, including molecular genetics, transcriptomics, and metabolomics, provides new technologies for studying cardiac metabolism to delineate new signalling pathways and research areas.
This review highlights the application and limitations of large-scale genomic, transcriptomic, and metabolomic technologies in studying cardiac metabolism during pathophysiological processes.
Answers are grounded in this paper and cite their sources.
Highlights omics for cardiac metabolism research; leaves open clinical translation pending validation.
Cell biology is in transition from reductionism to a more integrated science. Large-scale analysis of genome structure, gene expression, and metabolites are new technologies available for studying cardiac metabolism in diseases known to modify cardiac function. These technologies have several limitations and this review aims both to assess and take a critical look at some important results obtained in genomics restricted to molecular genetics, transcriptomics and metabolomics of cardiac metabolism in pathophysiological processes known to alter myocardial function. Therefore, our goal was to delineate new signalling pathways and new areas of research from the vast amount of data already published on genomics as applied to cardiac metabolism in diseases such as coronary heart disease, heart failure, and ischaemic reperfusion.
No takes yet. Share an insight, caveat, or question.
Samuel et al. (2008) conducted a review in Cardiac metabolism in diseases such as coronary heart disease, heart failure, and ischaemic reperfusion. Genomics (molecular genetics, transcriptomics, and metabolomics) was evaluated. Genomics, including molecular genetics, transcriptomics, and metabolomics, provides new technologies for studying cardiac metabolism to delineate new signalling pathways and research areas.
Synapse has enriched 10 related papers. Consider them for comparative context: